Clinical Trials

Are you an adult with both asthma and obesity? This study is testing whether a medicine called L-citrulline can help treat asthma and improve lung function in people who have obesity. To participate in this study, you must be 18 to 65 years old and have asthma and obesity. This study takes place in Durham, North Carolina.

Has your child been treated for an asthma attack with an oral corticosteroid medicine in the last 12 months? A study team will recruit 60 teens and young adults (between 12 and 21 years old) with persistent asthma who are at high risk for future exacerbation. This study examines the contribution of interleukin 1 beta (IL-1β), a protein that is involved in the inflammatory response, in asthma flare-ups. This study takes place in Chapel Hill, North Carolina.

The study is to investigate that the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling during an orthostatic challenge.

Do you have a high-risk pregnancy? This study will investigate the use of a non-invasive scan called fetal magnetocardiography to detect potential problems in the fetus in five high-risk pregnancy conditions associated with stillbirth. The scan is normally used to look at fetal heart rhythms. To participate in this study, you must be at least 18 years old and pregnant with one of the following: having a stillbirth in a previous pregnancy, carrying identical twins, or having a fetus that has been diagnosed with major congenital heart disease, fetal hydrops, or fetal gastroschisis. This study takes place in Madison and Milwaukee, Wisconsin.

Are you a woman who is postmenopausal or a man older than 65? This study will investigate the effects of oral progesterone for older women and testosterone for older men on QT intervals. QT intervals that are increased by medicine can lead to dangerous heart rhythm problems. Researchers hope to learn more about why this happens and how to deliver safer doses. This study is located in Indianapolis, Indiana.